Vasoconstrictor Potential of Coronary Aspirate From Patients Undergoing Stenting of Saphenous Vein Aortocoronary Bypass Grafts and Its Pharmacological Attenuation
暂无分享,去创建一个
S. Möhlenkamp | R. Erbel | H. Eggebrecht | B. Levkau | G. Heusch | R. Schulz | Thomas F M Konorza | P. Kleinbongard | M. Haude | D. Böse | H. Degen | M. Elter-Schulz | T. Baars | Sandra Schöner | T. Konorza
[1] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[2] F. Van de Werf,et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. , 2011, European heart journal.
[3] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .
[4] G. Heusch,et al. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. , 2010, Pharmacology & therapeutics.
[5] P. Ferdinandy,et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. , 2010, Cardiovascular research.
[6] S. Frisbee,et al. Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. , 2010, Physiological genomics.
[7] A. Kastrati,et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. , 2010, Journal of the American College of Cardiology.
[8] R. Virmani,et al. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. , 2010, Journal of the American College of Cardiology.
[9] Xiangbin Xu,et al. Direct relationship between levels of TNF-α expression and endothelial dysfunction in reperfusion injury , 2010, Basic Research in Cardiology.
[10] R. Erbel,et al. Coronary microembolization: from bedside to bench and back to bedside. , 2009, Circulation.
[11] A. Iskandrian,et al. Pretreatment with nitroprusside for microcirculatory protection in saphenous vein graft interventions. , 2009, The Journal of invasive cardiology.
[12] G. Heusch. Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve , 2009, Basic Research in Cardiology.
[13] Michael Weis,et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.
[14] Raimund Erbel,et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions , 2008, Basic Research in Cardiology.
[15] R. Jaffe,et al. Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention , 2008, Circulation.
[16] A. Balduini,et al. Tissue Factor in Patients with Acute Coronary Syndromes. Expression In , 2022 .
[17] A. Feldman,et al. TNF-&agr; Contributes to Endothelial Dysfunction by Upregulating Arginase in Ischemia/Reperfusion Injury , 2007 .
[18] R. Erbel,et al. Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. , 2007, American journal of physiology. Heart and circulatory physiology.
[19] A. Maseri,et al. Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside. , 2007, The American journal of cardiology.
[20] G. Maurer,et al. Active endothelin is an important vasoconstrictor in acute coronary thrombi , 2007, Thrombosis and Haemostasis.
[21] A. Feldman,et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[22] M. de Belder,et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes , 2006, Heart.
[23] E. Romagnoli,et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. , 2006, European heart journal.
[24] R. Erbel,et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. , 2006, Journal of the American College of Cardiology.
[25] N. Weissman,et al. Comparison of ruptured plaques in native coronary arteries and in saphenous vein grafts: an intravascular ultrasound study. , 2006, The American journal of cardiology.
[26] L. Kuo,et al. TNF-&agr; Contributes to Endothelial Dysfunction in Ischemia/Reperfusion Injury , 2005 .
[27] J. Herrmann. Peri-procedural myocardial injury: 2005 update. , 2005, European heart journal.
[28] A. Jacobs,et al. Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.
[29] V. Pasceri,et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. , 2005, The American journal of cardiology.
[30] Takashi Saito,et al. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. , 2005, American journal of physiology. Heart and circulatory physiology.
[31] M. Hersberger,et al. Inflammatory Markers at the Site of Ruptured Plaque in Acute Myocardial Infarction: Locally Increased Interleukin-6 and Serum Amyloid A but Decreased C-Reactive Protein , 2005, Circulation.
[32] M. Hori,et al. Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. , 2004, Journal of molecular and cellular cardiology.
[33] H. Figulla,et al. Intracoronary verapamil for reversal of no‐reflow during coronary angioplasty for acute myocardial infarction , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[34] C. Gibson,et al. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. , 2002, The Journal of invasive cardiology.
[35] G. Maurer,et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. , 2002, Blood.
[36] S. Sdringola,et al. Risk assessment of slow or no‐reflow phenomenon in aortocoronary vein graft percutaneous intervention , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[37] F. Cipollone,et al. Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.
[38] M. Kern,et al. The coronary no-reflow phenomenon: a review of mechanisms and therapies. , 2001, European heart journal.
[39] G. Caughey,et al. Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors1 , 2000, The Journal of Immunology.
[40] Y. Boie,et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. , 2000, Biochimica et biophysica acta.
[41] F. Rengo,et al. Intracoronary serotonin release after high-pressure coronary stenting. , 1999, The American journal of cardiology.
[42] T. Branchek,et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. , 1999, European journal of pharmacology.
[43] C. White,et al. Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. , 1998, American heart journal.
[44] Katherine C. Wu,et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. , 1998, Circulation.
[45] S. Hourani,et al. Activation of two sites by adenosine receptor agonists to cause relaxation in rat isolated mesenteric artery , 1997, British journal of pharmacology.
[46] W. O’Neill,et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. , 1996, Catheterization and cardiovascular diagnosis.
[47] Y. Nishimura. Characterization of 5‐hydroxytryptamine receptors mediating contractions in basilar arteries from stroke‐prone spontaneously hypertensive rats , 1996, British journal of pharmacology.
[48] M. Condorelli,et al. Local effect of serotonin released during coronary angioplasty. , 1994, The New England journal of medicine.
[49] M. Yacoub,et al. Interaction Between Thromboxane A2 and 5‐Hydroxytryptamine Receptor Subtpes in Human Coronary Arteries , 1993, Circulation.
[50] W. Roberts,et al. Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same men. , 1992, The American journal of cardiology.
[51] G. Heusch. Myocardial stunning: a role for calcium antagonists during ischaemia? , 1992, Cardiovascular research.
[52] M. Yanagisawa,et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[53] R. Jessup,et al. Studies In The Guinea‐pig With ICI 185,282: A Thromboxane A2 Receptor Antagonist , 1988, The Journal of pharmacy and pharmacology.
[54] R. Frye,et al. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. , 1987, Journal of the American College of Cardiology.
[55] E. Braunwald,et al. Effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with transient reperfusion. , 1986, Journal of the American College of Cardiology.
[56] G. FitzGerald,et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[57] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.
[58] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.
[59] E. Watson. Liquid chromatography with electrochemical detection for plasma norepinephrine and epinephrine. , 1981, Life sciences.
[60] M. Mulvany,et al. The active tension-length curve of vascular smooth muscle related to its cellular components , 1979, The Journal of general physiology.
[61] M. Mulvany,et al. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. , 1977, Circulation research.
[62] R. Kloner,et al. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. , 1974, The Journal of clinical investigation.